ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $75.59 million. The enterprise value is $84.97 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.05 million shares outstanding. The number of shares has increased by 10.52% in one year.
| Current Share Class | 9.05M |
| Shares Outstanding | 9.05M |
| Shares Change (YoY) | +10.52% |
| Shares Change (QoQ) | +1.60% |
| Owned by Insiders (%) | 27.95% |
| Owned by Institutions (%) | 18.37% |
| Float | 6.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.73 |
| Forward PS | n/a |
| PB Ratio | 2.79 |
| P/TBV Ratio | 2.80 |
| P/FCF Ratio | 61.71 |
| P/OCF Ratio | 30.54 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 16.41, with an EV/FCF ratio of 69.37.
| EV / Earnings | n/a |
| EV / Sales | 3.07 |
| EV / EBITDA | 16.41 |
| EV / EBIT | 34.69 |
| EV / FCF | 69.37 |
Financial Position
The company has a current ratio of 4.26, with a Debt / Equity ratio of 0.49.
| Current Ratio | 4.26 |
| Quick Ratio | 1.82 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 2.33 |
| Debt / FCF | 10.77 |
| Interest Coverage | 4.96 |
Financial Efficiency
Return on equity (ROE) is -3.81% and return on invested capital (ROIC) is 6.45%.
| Return on Equity (ROE) | -3.81% |
| Return on Assets (ROA) | 3.49% |
| Return on Invested Capital (ROIC) | 6.45% |
| Return on Capital Employed (ROCE) | 6.35% |
| Weighted Average Cost of Capital (WACC) | 5.50% |
| Revenue Per Employee | $378,687 |
| Profits Per Employee | -$14,247 |
| Employee Count | 73 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 1.98 |
Taxes
In the past 12 months, ImmuCell has paid $11,570 in taxes.
| Income Tax | 11,570 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +51.91% in the last 52 weeks. The beta is 0.31, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +51.91% |
| 50-Day Moving Average | 6.74 |
| 200-Day Moving Average | 6.29 |
| Relative Strength Index (RSI) | 72.85 |
| Average Volume (20 Days) | 26,014 |
Short Selling Information
The latest short interest is 34,248, so 0.38% of the outstanding shares have been sold short.
| Short Interest | 34,248 |
| Short Previous Month | 27,331 |
| Short % of Shares Out | 0.38% |
| Short % of Float | 0.57% |
| Short Ratio (days to cover) | 2.52 |
Income Statement
In the last 12 months, ImmuCell had revenue of $27.64 million and -$1.04 million in losses. Loss per share was -$0.12.
| Revenue | 27.64M |
| Gross Profit | 11.45M |
| Operating Income | 2.45M |
| Pretax Income | -1.03M |
| Net Income | -1.04M |
| EBITDA | 5.18M |
| EBIT | 2.45M |
| Loss Per Share | -$0.12 |
Full Income StatementBalance Sheet
The company has $3.81 million in cash and $13.19 million in debt, with a net cash position of -$9.39 million or -$1.04 per share.
| Cash & Cash Equivalents | 3.81M |
| Total Debt | 13.19M |
| Net Cash | -9.39M |
| Net Cash Per Share | -$1.04 |
| Equity (Book Value) | 27.06M |
| Book Value Per Share | 2.99 |
| Working Capital | 12.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $2.48 million and capital expenditures -$1.25 million, giving a free cash flow of $1.22 million.
| Operating Cash Flow | 2.48M |
| Capital Expenditures | -1.25M |
| Depreciation & Amortization | 2.73M |
| Net Borrowing | -1.48M |
| Free Cash Flow | 1.22M |
| FCF Per Share | $0.14 |
Full Cash Flow StatementMargins
Gross margin is 41.40%, with operating and profit margins of 8.86% and -3.76%.
| Gross Margin | 41.40% |
| Operating Margin | 8.86% |
| Pretax Margin | -3.72% |
| Profit Margin | -3.76% |
| EBITDA Margin | 18.73% |
| EBIT Margin | 8.86% |
| FCF Margin | 4.43% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.52% |
| Shareholder Yield | -10.52% |
| Earnings Yield | -1.38% |
| FCF Yield | 1.62% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmuCell has an Altman Z-Score of 2.73 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 7 |
